Previous 10 | Next 10 |
home / stock / cmndf / cmndf news
Palm Beach, FL – May 24, 2022 – FinancialNewsMedia.com News Commentary – The Global psychedelic drugs market has been steadily rising for the past few years and is projected to continue at a faster pace in years to come. The rising prevalence of mental depre...
P re-clinical trial based on the proprietary combination demonstrate s high safety profile in addition to a significant suppressive effect on alcohol consumption Vancouver, May 24, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY...
Pre-clinical trial demonstrated high safety profile in addition to a significant suppressive effect on alcohol consumption VANCOUVER, May 19, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“ Clearmind ” or the ...
Clearmind aims to initiate clinical trials with CMND-100 by year’ s end Vancouver, May 13, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“ Clearmind ” or the " Company "), a biotech company focused on disco...
Pre-clinical trials based on proprietary combination demonstrate significant suppressive effect on alcohol consumption TORONTO, May 10, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“ Clearmind ” or the " Company ")...
Prof . Schütz’ main research interests focus on clinical interventions and health service in substance use disorders and mental health diagnoses ; Prof. Weiser specializes in psychiatric disorders such as substance abuse and depression ....
TORONTO, March 24, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ( CSE: CMND, FSE: CWY0 , OTCMKTS: CMNDF ) (“ Clearmind ” or the " Company "), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived th...
Toronto, Ontario--(Newsfile Corp. - March 23, 2022) - Clearmind Medicine Inc. ( CSE: CMND) (FSE: CWY0) (OTC Pink: CMNDF ) (" Clearmind " or the " Company "), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics ...
SciSparc Announces Positive Results from Psychedelic-Based Pre-Clinical Trial Results demonstrated that combining SciSparc's CannAmide™ with Clearmind's MEAI has the potential to reduce alcohol consumption PR Newswire TEL AVIV, Israel , March 17, 2022 ...
Two pre-clinical trials based on MEAI exhibited a significant suppressive effect on alcohol consumption in mice TORONTO, March 17, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the "Company") today an...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq and CSE: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated h...
The first episode, "Psychedelic Novelty - Before it was Cool," introduces the company's proprietary molecule MEAI VANCOUVER, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“ Clearmind ” or the " company ...
VANCOUVER, Sept. 25, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“ Clearmind ” or the " Company "), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertr...